Clinical Trial Update: SHR0302 and Steroid As First Line Therapy for Chronic GVHD [EARLY_Phase 1]

View source ↗

Summary

An early-phase clinical trial evaluating SHR0302 with steroids as first-line therapy for chronic graft-versus-host disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• SHR0302 (SHR0302)
• Steroid (steroid)

Snippet

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: Chronic GVHD | EARLY_Phase 1 | Status: COMPLETED